Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.61 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.61 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.61 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23767406 | 1.00 | GNAI3 (0.61) | GNAI3GNAO1GNAI1PAOXSIGMAR1 | |
| SCHEMBL11737892 | 0.97 | GNAI3 (0.65) | GNAI3GNAO1GNAI1PAOXSIGMAR1 | |
| SCHEMBL10725884 | 0.97 | GNAI3 (0.65) | GNAI3GNAO1GNAI1PAOXSIGMAR1 | |
| SCHEMBL4304828 | 0.97 | GNAI3 (0.65) | GNAI3GNAO1GNAI1PAOXSIGMAR1 | |
| SCHEMBL11741978 | 0.97 | GNAI3 (0.65) | GNAI3GNAO1GNAI1PAOXSIGMAR1 | |
| SCHEMBL5770286 | 0.97 | GNAI3 (0.65) | GNAI3GNAO1GNAI1PAOXSIGMAR1 | |
| SCHEMBL10520655 | 0.97 | GNAI3 (0.65) | GNAI3GNAO1GNAI1PAOXSIGMAR1 | |
| SCHEMBL11739779 | 0.97 | GNAI3 (0.65) | GNAI3GNAO1GNAI1PAOXSIGMAR1 | |
| SCHEMBL11739399 | 0.97 | GNAI3 (0.65) | GNAI3GNAO1GNAI1PAOXSIGMAR1 | |
| SCHEMBL11740614 | 0.97 | GNAI3 (0.65) | GNAI3GNAO1GNAI1PAOXSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024098053-A1 | POLYMER-NUCLEIC ACID NANOPARTICLES FOR GENE EDITING | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| US-11827611-B2 | Ubiquitin-specific peptidase 24 inhibitor, medicinal composition including the same and method of delaying or reversing multidrug resistance in cancers using the same | NATIONAL CHENG KUNG UNIVERSITY (TW) | 2023-11-28 | — | — | US | disclosed |
| US-20230321081-A1 | MASITINIB FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AB SCIENCE (FR) | 2023-10-12 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11767312-B2 | Phthalazinone compound, and preparation method therefor and medical use thereof | GENENTECH, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767312-B2 | Phthalazinone compound, and preparation method therefor and medical use thereof | GENENTECH, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20070249655-A1 | 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones | KESTELEYN BART R R | 2007-10-25 | — | — | US | disclosed |
| US-20070249655-A1 | 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones | KESTELEYN BART R R | 2007-10-25 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-7232825-B2 | Phenylaminopyrimidine derivatives and methods of use | CHEN GUOQING P | 2007-06-19 | — | — | US | disclosed |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-22 | — | — | US | disclosed |
| JP-2005120014-A | METHOD FOR PRODUCING ARYLMETHYLPIPERAZINE DERIVATIVE | TORAY FINE CHEMICALS CO LTD | 2005-05-12 | — | — | JP | disclosed |
| EP-0546583-B1 | Piperazinyl-and piperidinyl-cyclohexanols | BRISTOL MYERS SQUIBB CO (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0546583-A1 | Piperazinyl-and piperidinyl-cyclohexanols | Bristol-Myers Squibb Company (US) | 1993-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | GNAI3 1131/4885GNAO1 1472/4885GNAI1 988/4885 |
| US-20070249655-A1 | 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones | CYP8B1, CYP2S1, CYC1 | GNAI3 4071/4885GNAO1 1526/4885GNAI1 3064/4885 |
| US-20230321081-A1 | MASITINIB FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | ACP3, KLK3, PHKA1 | GNAI3 828/4885GNAO1 1778/4885GNAI1 1112/4885 |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | PLK2, CDK2, MAP3K15 | GNAI3 1078/4885GNAO1 1463/4885GNAI1 1226/4885 |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | GNAI3 1283/4885GNAO1 2211/4885GNAI1 1986/4885 |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | GNAI3 796/4885GNAO1 1565/4885GNAI1 757/4885 |
| US-11767312-B2 | Phthalazinone compound, and preparation method therefor and medical use thereof | CYP17A1, AR, NR5A1 | GNAI3 2458/4885GNAO1 1499/4885GNAI1 1503/4885 |
| US-11827611-B2 | Ubiquitin-specific peptidase 24 inhibitor, medicinal composition including the same and method of delaying or reversing multidrug resistance in cancers using the same | USP24, USP47, USP39 | GNAI3 2477/4885GNAO1 4394/4885GNAI1 1907/4885 |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | MIF, MMP12, METAP1 | GNAI3 2132/4885GNAO1 3817/4885GNAI1 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.